Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis

Vaccine

Volumn 31, Issue 13, 2013, Pages 1748-1751

  Wongsaroj, Patarapha ^a   Udomchaisakul, Piyada ^a   Tepsumethanon, Saowaluck ^a   Khawplod, Pakamatz ^a   Tantawichien, Terapong ^a,b  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Intradermal injection; Pre exposure prophylaxis; Rabies vaccination

Indexed keywords

NEUTRALIZING ANTIBODY; RABIES IMMUNOGLOBULIN; RABIES VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; DRUG SAFETY; ERYTHEMA; FEVER; GEOMETRY; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; PAIN; PATIENT TRANSPORT; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; RABIES VIRUS; VACCINATION; VERO CELL; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DRUG TOXICITY; FEMALE; FRANCE; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; RABIES; RABIES VACCINES; YOUNG ADULT;

EID: 84875260116     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.01.035     Document Type: Article

References (14)

1. World Health Organization Rabies vaccines. WHO position paper. Wkly Epidemiol Rec 2010, 85:309-320.
2. Meeting Report Preventing the incurable: Asian rabies experts advocate rabies control. Vaccine 2006, 24:3045-3049.
3. Shantavasinkul P., Tantawichien T., Wacharapluesadee S., Jeamanukoolkit A., Udomchaisakul P., Chattranukulchai P., et al. Failure of rabies postexposure prophylaxis in patients presenting with unusual manifestations. Clin Infect Dis 2010, 50(1):77-79.
4. Wilde H., Sirikawin S., Sabcharoen A., Kingnate D., Tantawichien T., Harischandra P.A., et al. Failure of postexposure treatment of rabies in children. Clin Infect Dis 1990, 22(2):228-232.
5. Center of Disease Control (CDC) Human Rabies Prevention-United States: recommendations of the Advisory Committee of Immunization Practice (ACIP). MMWR 2008, 57(RR-3):1-36.
6. World Health Organization Expert Consultation on rabies. World Health Organ Tech Rep Ser 2005, 931:1-88.
7. Smith J.S., Yager P.A., Baer G.M. A rapid reproducible test for determining rabies neutralizing antibody. Bull World Health Organ 1973, 48:535-541.
8. Sabchareon A., Chantavanich P., Pasuralertsakul S., Pojjaroen-Anant C., Prarinyanupharb V., Attanath P., et al. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. Pediatr Infect Dis J 1998, 17:1001-1007.
9. Tantawichien T., Benjavongkulchai M., Limsuwan K., Khawplod P., Kaewchompoo W., Chomchey P., et al. Antibody response after a four-site intradermal booster vaccination with cell culture rabies vaccine. Clin Infect Dis 1999, 28:1100-1103.
10. Burridge M.J., Bear G.M., Sumner J.W. Intradermal immunization with human diploid cell rabies vaccine: serological and clinical responses of immunized persons to intradermal booster vaccination. Am J Public Health 1984, 74(2):503-505.
11. Suwansrinon K., Wilde H., Benjavongkulchai M., Banjongkasaena U., Lertjarutorn S., Boonchang S., et al. Survival of neutralizing antibody in previously rabies vaccine subjects: a prospective study showing long lasting immunity. Vaccine 2006, 24(18):3878-3880.
12. Kamoltham T., Thinyounyong W., Khawplod P., Phraisuwan P., Phongchamnaphai P., Anders G., et al. Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe. J Pediatr 2007, 151(2):173-177.
13. Strady A., Lang J., Lienard M., Blondeau C., Jaussaud R., Plotkin S.A. Antibody persistence following preexposure regimens of cell culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J Infect Dis 1998, 177:1290-1295.
14. Vien N.C., Feroldi E., Lang J. Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children. Trans R Soc Trop Med Hyg 2008, 102:294-296.